Hyperparathyroidism secondary

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
H Endocrinology (ATC H) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

3 trials
  • Amgen Inc. Commercial
    ETELCALCETIDE
    2023-506471-10-00 8 countries 2019 n=26
    Recruiting
  • Pathalys Pharma Inc. Commercial
    UPACICALCET SODIUM HYDRATE
    2023-504338-24-00 4 countries 2023 n=120
    Ended
  • Pathalys Pharma Inc. Commercial
    UPACICALCET SODIUM HYDRATE
    2023-504339-41-00 4 countries 2023 n=100
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pathalys Pharma Inc. Commercial 2 Phase III 0
Amgen Inc. Commercial 1 Phase III 1
New trials by year
2019
1
2023
2
← All indication landscapes